ICAM5

Across TCGA pan-cancer cohorts, ICAM5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ICAM5 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ICAM5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ICAM5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ICAM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.133	0.710	.001	45	view →
LSCC	DFS	Median	All	0.841	0.692	.016	14	view →
LUAD	DFS	Median	III,IV	0.426	0.973	.004	7	view →
HNSC	DFS	Median	All	0.893	0.749	.033	5	view →
GBM	DFS	Median	All	0.834	0.662	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ICAM5–PDAC (DFS)

Open the PDAC breakdown →